Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. Read more >>

Share this post